Adalimumab Plus Methotrexate for the Treatment of Pediatric Uveitis

• Status: Recruiting
• Trial end date: 2021-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to determine the efficacy and safety of ADA plus MTX for the treatment in non-infectious pediatric panuveitis.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Adalimumab; Methotrexate

Criteria

Inclusion Criteria:

• Clinical diagnosis of non-infectious panuveitis

• Age from 2 to 16 years old

• Vision threatening non-infectious uveitis hadn't received standardized systematic treatment before

Exclusion Criteria:

• Patients who had active infection (including hepatitis B or C infection, tuberculosis), malignancy diseases, or bilateral irreversible blindness and any other contraindications of ADA

• previous exposure to another biologic agent